Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study in collaboration with The University of Texas MD Anderson Cancer Center, ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
Agilent Technologies and BaseSolve announce a co-marketing agreement to offer a U.S.-focused integrated solution for NGS workflows. This collaboration provides a streamlined genomics workflow by ...
A team from University of Toronto Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell—a new approach to drug discovery that has already yielded some promising ...
Scientists can peer into cells to get a limited view of their activity using microscopes and other tools. However, cells and the molecular events within them are dynamic, and developmental processes, ...
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results